Simvastatin for Treating Erectile Dysfunction (STED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00947323
Recruitment Status : Completed
First Posted : July 28, 2009
Last Update Posted : September 27, 2010
Information provided by:
Santa Casa de Porto Alegre

July 27, 2009
July 28, 2009
September 27, 2010
January 2006
July 2008   (Final data collection date for primary outcome measure)
Penile erection
Same as current
Complete list of historical versions of study NCT00947323 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Simvastatin for Treating Erectile Dysfunction
The Effect of Simvastatin in the Penile Erection: a Randomized, Double-blind Clinical Trial
This is a randomized clinical trial, double-blind, placebo controlled, to verify if simvastatin can improve erectile dysfunction in men with endothelial dysfunction, without any cardiac disease.It is hypothesized that the simvastatin can improve the endothelial function, improving the nitric oxide liberation in corpora cavernosa of the penis, resulting in improvement of erection.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
  • Erectile Dysfunction
  • Vascular Disease Detected
  • C Reactive Protein
  • Drug: Simvastatin
    simvastatin 20 daily for six months.
  • Drug: Placebo
  • Placebo Comparator: placebo
    Intervention: Drug: Placebo
  • Experimental: Simvastatin
    Treatment arm.
    Intervention: Drug: Simvastatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2008
July 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Erectile dysfunction
  • Elevated C reactive protein
  • Able to adhere the protocol

Exclusion Criteria:

  • Diabetes mellitus
  • Cardiac disease
  • Cerebral vascular disease
  • Hypogonadism
  • Any contraindication to simvastatin
Sexes Eligible for Study: Male
35 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Eduardo Touguinha Mastalir, Santa Casa de Porto Alegre
Santa Casa de Porto Alegre
Not Provided
Not Provided
Santa Casa de Porto Alegre
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP